Clinical trial
Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects…
NCT00097279 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00097279 |
|---|---|
| Title | Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes |
| Official title | A Multicenter, Open-Label, Randomised Trial to Compare the Efficacy and Safety of NovoLog Mix 70/30 BID in Combination With Metformin and Pioglitazone to Metformin and Pioglitazone Alone in Insulin Naïve Subjects With Type 2 Diabetes |
| Acronym | ACTION |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | biphasic insulin aspart, pioglitazone, metformin |
| Enrollment | 230 |
| Start date | Aug 1, 2004 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Nov 22, 2004 |
| Last update posted | Jan 11, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: